CBDV (cannabidivarin) is a non-psychoactive cannabinoid found naturally in the cannabis plant, closely related to CBD but with a slightly different chemical structure that gives it distinct properties. It won’t get you high, and it’s currently being studied for potential benefits in epilepsy, autism spectrum disorder, nausea, and muscular dystrophy. While research is still early, CBDV has shown enough promise that pharmaceutical companies have moved it into human clinical trials.
How CBDV Differs From CBD
CBDV belongs to a group called “varin” cannabinoids, which contain two fewer carbon atoms in their side chain compared to their more familiar counterparts. Where CBD has a five-carbon side chain, CBDV has a three-carbon (propyl) side chain. This small structural difference changes how the molecule interacts with receptors in your body, giving CBDV its own pharmacological profile.
Both compounds start from a shared biosynthetic pathway inside the cannabis plant. CBDV’s precursor is cannabigerovarin acid (CBGVA), which is built from a molecule called divarinolic acid. Enzymes in the plant then convert CBGVA into CBDV’s acidic form, which becomes the neutral CBDV we recognize when exposed to heat or light, a process called decarboxylation. This is the same general process that converts THCA into THC when you heat cannabis, just with different starting materials.
CBDV is most abundant in certain landrace cannabis strains from South and Central Asia, particularly indica varieties. It tends to appear in higher concentrations in plants that are naturally lower in THC.
How CBDV Works in the Body
One of CBDV’s primary targets is a receptor called TRPV1, sometimes nicknamed the “capsaicin receptor” because it’s the same receptor that responds to chili peppers. TRPV1 is a channel that controls the flow of calcium and sodium into cells, and it plays roles in pain signaling, inflammation, and nerve cell activity. CBDV activates TRPV1 with high affinity, triggering a distinctive two-phase pattern of calcium flowing into cells.
This TRPV1 interaction appears to have downstream effects on nerve cells. In laboratory studies on brain tissue, CBDV promoted cell survival, cell proliferation, and the development of new neurons through this TRPV1-dependent mechanism. Notably, CBDV does not appear to act as an inverse agonist at the CB1 receptor (the receptor THC activates to produce a high), which means it avoids many of the side effects associated with compounds that block that receptor.
Epilepsy and Seizure Research
The most advanced clinical research on CBDV involves epilepsy, with GW Pharmaceuticals (the same company behind the CBD-based drug Epidiolex) leading trials. In a phase 1 trial for girls with Rett syndrome, a genetic condition that causes severe seizures, patients received a plant-based CBDV oil extract at doses up to 10 mg/kg/day. Doses above that threshold were linked to increased drowsiness.
The results were striking: the median reduction in seizure frequency was 82%, with a range of 7% to 98%. All five patients in the trial experienced some reduction. Four of the five saw seizures drop by more than half, and three of those saw reductions greater than 75%. In a separate adult trial focused on focal epilepsy, CBDV produced a 41% reduction in seizure frequency. These are small studies, but the effect sizes caught researchers’ attention.
Autism Spectrum Disorder
CBDV is one of the first cannabinoids to enter clinical investigation specifically for autism. The rationale centers on a theory that autism involves imbalances between excitatory and inhibitory signaling in the brain, specifically between the neurotransmitters glutamate (excitatory) and GABA (inhibitory). In a single-dose brain imaging trial, researchers used magnetic resonance spectroscopy to observe how CBDV affected these systems in adults with and without autism.
The study found that CBDV shifted glutamate levels in a brain region called the basal ganglia, though researchers noted the long-term clinical significance of this shift remains unclear. A larger clinical trial (registered as NCT03202303) has investigated CBDV’s impact on irritability in autistic children, making it the first cannabinoid trial specifically designed for this population. Results from that trial are still being evaluated, so the picture is incomplete.
Anti-Nausea Potential
Animal research published in the British Journal of Pharmacology found that CBDV reduced nausea-related behavior in rats at high doses (200 mg/kg). Importantly, CBDV did not produce the nausea-inducing effects seen with some other compounds that block the CB1 receptor, and it didn’t alter normal eating behavior or food enjoyment. The anti-nausea effect appeared to work through a different mechanism than THC, which also suppresses nausea but does so through CB1 activation. This suggests CBDV could potentially offer nausea relief without the psychoactive effects of THC, though this hasn’t been tested in humans yet.
Muscular Dystrophy Findings
In a preclinical study on mice with Duchenne muscular dystrophy, CBDV at 60 mg/kg prevented the loss of movement ability, reduced inflammation in muscle tissue, and restored a cellular cleanup process called autophagy that goes awry in dystrophic muscle. Treated mice performed significantly better on tests of coordination and muscle strength, matching the performance of healthy mice in some measures.
At the molecular level, CBDV reduced elevated levels of several inflammatory markers in both the leg muscles and the diaphragm. It also lowered levels of two key inflammatory proteins to levels comparable to healthy mice. CBD performed similarly in many of these tests, though it was more consistent at reducing all inflammatory markers. Both compounds restored muscle function even in older mice where the disease had progressed significantly, with two weeks of treatment producing full recovery of movement ability.
Side Effects and Safety
Clinical data on CBDV specifically is limited, but the side effect profile appears similar to CBD. The most commonly reported issues across cannabinoid trials are diarrhea, drowsiness, sedation, and upper respiratory symptoms. Most side effects are rated as mild or moderate. In the Rett syndrome trial, the main dose-limiting factor was sleepiness at doses above 10 mg/kg/day. Gastrointestinal symptoms like decreased appetite and vomiting have also been noted in related cannabinoid studies.
Legal Status
CBDV’s legal status follows the same framework as other hemp-derived cannabinoids in the United States. The 2018 Farm Bill explicitly included “cannabinoids” in its definition of lawful hemp, meaning CBDV derived from hemp plants containing less than 0.3% THC is federally legal. However, state laws vary, and the regulatory landscape for minor cannabinoids remains less clear-cut than for CBD. CBDV is not currently classified as a controlled substance on its own, and because it produces no psychoactive effects, it hasn’t drawn the same scrutiny as THC-related compounds.
CBDV is available in some specialty cannabinoid products, typically as isolates, tinctures, or included in broad-spectrum hemp extracts. Because it’s a minor cannabinoid, concentrations in standard CBD products tend to be very low unless the product is specifically formulated to include it.